UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053279
Receipt number R000059978
Scientific Title Impact of systemic therapy on the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolization
Date of disclosure of the study information 2024/01/05
Last modified on 2024/01/05 18:51:02

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Impact of systemic therapy on the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolization

Acronym

Impact of systemic therapy on the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolization

Scientific Title

Impact of systemic therapy on the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolization

Scientific Title:Acronym

Impact of systemic therapy on the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolization

Region

Japan


Condition

Condition

hepatocellular carcinoma

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To assess the influence of systemic therapy to the serum vascular endothelial growth factor levels in patients with hepatocellular carcinoma after transarterial chemoembolization

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Comparing the amount of change in VEGF levels before and after Transarterial Chemoembolization for each systemic drug therapy

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with unresectable advanced hepatocellular carcinoma (HCC) who are scheduled for Transarterial Chemoembolization

Key exclusion criteria

exclusion criterion
1. Child-Pugh C patients:
2. Patients with esophageal varices that may cause bleeding
3. Patients with gastrointestinal bleeding within 1 month
4. Patients who are pregnant, may be pregnant, or are breastfeeding
5. Patients with severe hypersensitivity to the components of this drug
6. Patients with severe heart failure or renal failure
7. Patients with malignant tumors other than hepatocellular carcinoma
8. Other patients unsuitable as subjects by the research director

Target sample size

300


Research contact person

Name of lead principal investigator

1st name hisashi
Middle name
Last name hidaka

Organization

Kitasato University School of Medicine

Division name

Department of Gastroenterology

Zip code

252-0374

Address

1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0375, Japan

TEL

0427788111

Email

hisashi7@kitasato-u.ac.jp


Public contact

Name of contact person

1st name Haruki
Middle name
Last name Uojima

Organization

Kitasato University School of Medicine

Division name

Department of Gastroenterology

Zip code

252-0374

Address

1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa

TEL

0427788111

Homepage URL


Email

kiruha@kitasato-u.ac.jp


Sponsor or person

Institute

Kitasato University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Kitasato University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of kitasato university

Address

1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa

Tel

0427788111

Email

rinrib@med.kitasato-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 01 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 09 Month 06 Day

Date of IRB

2023 Year 10 Month 19 Day

Anticipated trial start date

2023 Year 10 Month 22 Day

Last follow-up date

2025 Year 07 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

To compare the changes in VEGF levels after TAE for enrolled patients, VEGF was measured at three time points for each patient (before treatment, 3 days after treatment, and 56 days after treatment),


Management information

Registered date

2024 Year 01 Month 05 Day

Last modified on

2024 Year 01 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059978


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name